Q4 2022 Results
Company overview
Financial review
2023 priorities
Appendix
expect steady ramp in 2023 similar to Entresto® US trajectory
GROWTH
LEQVIO®
LeqvioⓇ in line with initial EntrestoⓇ launch
US monthly sales evolution
USD m
50
50
40
40
30
30
20
20
10
10
Leqvio®
EntrestoⓇ
или
2023 focus
US: Accelerate adoption
Enable new facilities to order LeqvioⓇ (breadth)
Accelerate growth among prescribers (depth)
Support HCPs with acquisition/reimbursement process
Expect gradual conversion from Free Trial offer
Ex-US: Continue rollout
Expand prescriber breadth in UK
Anticipate regulatory approval in additional geographies
including China (Q4 2023)
0
6
12
18
Prepare for anticipated launches in China/Japan/Spain
24
30
36
Months since launch
*Leqvio® is administered initially, again at 3 months, and then once every 6 months. **Novartis has obtained global rights to develop, manufacture and commercialize LeqvioⓇ under a license agreement with Alnylam Pharmaceuticals.
30 Investor Relations | Q4 2022 Results
✓ NOVARTIS | Reimagining MedicineView entire presentation